Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018222935) CHIMERIC ANTIGEN RECEPTORS TARGETING FLT3
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/222935 International Application No.: PCT/US2018/035492
Publication Date: 06.12.2018 International Filing Date: 31.05.2018
IPC:
C07K 16/28 (2006.01) ,A61K 35/17 (2015.01) ,C07K 14/725 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
[IPC code unknown for A61K 35/17]
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
14
Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435
from animals; from humans
705
Receptors; Cell surface antigens; Cell surface determinants
725
T-cell receptors
Applicants:
PFIZER INC. [US/US]; 235 East 42nd Street New York, New York 10017, US
Inventors:
SASU, Barbra Johnson; US
DETTLING, Danielle Elizabeth; US
SOMMER, Cesar Adolfo; US
YEUNG, Yik Andy; US
HAMZE, Moustafa Marc; FR
Agent:
JOSHI, Trupti P.; US
MAYER, Mika R.; US
ROY, Madhuri; US
Priority Data:
62/514,57402.06.2017US
62/514,63402.06.2017US
62/660,90820.04.2018US
Title (EN) CHIMERIC ANTIGEN RECEPTORS TARGETING FLT3
(FR) RÉCEPTEURS D'ANTIGÈNES CHIMÉRIQUES CIBLANT FLT3
Abstract:
(EN) Provided herein are antibodies that specifically bind to Fms-like tyrosine kinase 3 (FLT3), chimeric antigen receptors (CARs) that specifically bind to FLT3, and engineered immune cells expressing such CARs (e.g. FLT3-specific CAR-T cells). The invention also provides making such antibodies, CARs, and engineered immune cells. The invention also provides using such antibodies, CARs, and engineered immune cells, for example for the treatment of a condition associated with malignant cells expressing FLT3 (e.g., cancer).
(FR) La présente invention concerne des anticorps qui se lient spécifiquement à la tyrosine kinase 3 de type Fms (FLT3), des récepteurs d'antigènes chimériques (CAR) qui se lient spécifiquement à FLT3, et des cellules immunitaires génétiquement modifiées exprimant de tels CAR (par exemple des cellules CAR-T spécifiques de FLT3). L'invention concerne également la fabrication de tels anticorps, CAR et cellules immunitaires génétiquement modifiées. L'invention concerne également l'utilisation de tels anticorps, CAR et cellules immunitaires génétiquement modifiées, par exemple pour le traitement d'un état associé à des cellules malignes exprimant FLT3 (par exemple, le cancer).
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)